Filing Flows

Filing Flows › United Therapeutics (UTHR) › Next earnings date

United Therapeutics (UTHR) earnings: missed the estimate

United Therapeutics (UTHR) reported on Nov 4, 2026 and missed the EPS estimate: $5.71 against $6.04 (-5.5%). Revenue was $832M for Q3 2026, +4% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−5.5% vs estimate
Beat rate60%

The last report

United Therapeutics reported revenue of $832M for the third quarter 2026 (+4% Y/Y), net earnings $259M: Total Tyvaso $504M, Orenitram $145M, Remodulin $122M, Unituxin $52.3M. How it makes money → · Every quarter →

United Therapeutics: EPS against the estimate, last 5 reportsUnited Therapeutics: EPS against the estimate, last 5 reportsEstimateReported$6.96$7.16Oct 25$6.76$7.70Feb 26$6.86$5.82May 26$6.86$7.27Aug 26$6.04$5.71Nov 26
Latest (Nov 26): Estimate $6.04, Reported $5.71.
UTHR: the stock's move on each reportUTHR: the stock's move on each reportAug 5, 2026+2.7%May 6, 2026-0.5%Feb 25, 2026+6.4%Oct 29, 2025+9.2%

United Therapeutics' latest quarter

United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.

Questions

Did United Therapeutics beat earnings?

United Therapeutics (UTHR) reported on Nov 4, 2026 and missed the EPS estimate: $5.71 against $6.04 (-5.5%).

When does UTHR report earnings?

The next date is not set yet.

Does United Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.